336 related articles for article (PubMed ID: 24809052)
1. Kallikreins as biomarkers for prostate cancer.
Hong SK
Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
[TBL] [Abstract][Full Text] [Related]
2. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
Ulmert D; Vickers AJ; Scher HI; Becker C; Iversen P; Frankel D; Jensen JK; Olesen TK; Lilja H
Clin Chem Lab Med; 2012 Nov; 50(11):1993-8. PubMed ID: 22718641
[TBL] [Abstract][Full Text] [Related]
3. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.
Thorek DL; Evans MJ; Carlsson SV; Ulmert D; Lilja H
Thromb Haemost; 2013 Sep; 110(3):484-92. PubMed ID: 23903407
[TBL] [Abstract][Full Text] [Related]
5. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781
[TBL] [Abstract][Full Text] [Related]
6. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.
Rittenhouse HG; Finlay JA; Mikolajczyk SD; Partin AW
Crit Rev Clin Lab Sci; 1998 Aug; 35(4):275-368. PubMed ID: 9759557
[TBL] [Abstract][Full Text] [Related]
7. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
8. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H
Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522
[TBL] [Abstract][Full Text] [Related]
9. Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D
Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300
[TBL] [Abstract][Full Text] [Related]
10. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches.
Veveris-Lowe TL; Kruger SJ; Walsh T; Gardiner RA; Clements JA
Semin Thromb Hemost; 2007 Feb; 33(1):87-99. PubMed ID: 17253195
[TBL] [Abstract][Full Text] [Related]
11. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
12. Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Ulmert D; O'Brien MF; Bjartell AS; Lilja H
Nat Rev Urol; 2009 Jul; 6(7):384-91. PubMed ID: 19578355
[TBL] [Abstract][Full Text] [Related]
13. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
Benchikh A; Savage C; Cronin A; Salama G; Villers A; Lilja H; Vickers A
BMC Cancer; 2010 Nov; 10():635. PubMed ID: 21092177
[TBL] [Abstract][Full Text] [Related]
14. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.
Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP
Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124
[TBL] [Abstract][Full Text] [Related]
15. PSA and other tissue kallikreins for prostate cancer detection.
Stephan C; Jung K; Lein M; Diamandis EP
Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
[TBL] [Abstract][Full Text] [Related]
16. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
17. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
18. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
19. Activation and activity of glycosylated KLKs 3, 4 and 11.
Guo S; Briza P; Magdolen V; Brandstetter H; Goettig P
Biol Chem; 2018 Sep; 399(9):1009-1022. PubMed ID: 29975661
[TBL] [Abstract][Full Text] [Related]
20. [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis].
Lein M; Stephan C; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Jul; 39(4):313-23. PubMed ID: 10957772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
